Treatment and timing in invasive mould disease

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 1, 2011, Pages

  Maertens, Johan ^a   Groll, Andreas H ^b   Cordonnier, Catherine ^c   de la Cámara, Rafael ^d   Roilides, Emmanuel ^e   Marchetti, Oscar ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c HENRI MONDOR HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Aspergillosis; Empirical therapy; Invasive fungal disease; Pre emptive therapy

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; RAPAMYCIN; VORICONAZOLE;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; CANCER CHEMOTHERAPY; CANDIDA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; DRUG MONITORING; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNOCOMPROMISED PATIENT; INVASIVE ASPERGILLOSIS; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHUMAN; PSEUDALLESCHERIASIS; RELAPSE; REVIEW; SYSTEMIC MYCOSIS; ZYGOMYCETES;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; TIME FACTORS;

EID: 78650542722     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq440     Document Type: Review

References (50)

1. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis, and management in immunocompromised patients. Drugs 2007; 67: 1567-604.
2. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45: 205-16.
3. Meersseman W, Vandecasteele SJ, Wilmer A et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170: 621-5.
4. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20: 581-607.
5. von Eiff M, Roos N, Schulten R et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-7.
6. Greene RE, Schlamm HT, Oestmann J-W et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-9.
7. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
8. Gonzalez AV, Ullmann AJ, Almyroudis NG et al. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw 2008; 6: 175-82.
9. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
10. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
11. Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46: 1401-8.
12. Wingard JR, Carter SL, Walsh TJ et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 2010 Sep 8. [Epub ahead of print].
13. Marks DI, Kibbler C, Pagliugi A et al. Voriconazole versus itraconazole for primary prophylaxis of invasive fungal infection in allogeneic hematopoietic cell transplant (HCT) recipients. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract M-1249a. American Society for Microbiology, Washington, DC, USA.
14. Marr KA, Balajee SA, McLaughlin L et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190: 641-9.
15. Maertens J, Buvé K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw 2008; 6: 183-9.
16. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis-has the principle been proven? N Engl J Med 2007; 356: 409-11.
17. Pagano L, Akova M, Dimopoulos G et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 2011; 66 Suppl 1: i5-14.
18. Cuenca-Estrella M, Bassetti M, Lass-Flörl C et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011; 66 Suppl 1: i15-24.
19. Cordonnier C, Einsele H, Rovira M et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study: on behalf of the VOSIFI study group and the infectious diseases working party of the EBMT. Blood 2008; 112: 1159.
20. Klastersky J. Antifungal therapy in patients with fever and neutropenia-more rational and less empirical? NEnglJMed2004; 351: 1445-7.
21. Maertens J, Theunissen K, Lodewyck T et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 2007; 50 Suppl 1: 2-17.
22. De Pauw B. Between over- and under-treatment of invasive fungal disease. Clin Infect Dis 2005; 41: 1251-3.
23. Herbrecht R, Berceanu A. b-D-Glucan detection test: a step toward pre-emptive therapy for fungal infections in leukemic patients? Clin Infect Dis 2008; 46: 886-9.
24. De Pauw B, Walsh TJ, Donnelly PJ et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
25. Leeflang MM, Debets-Ossenkopp YJ, Visser CE et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev 2008; 8: CD007394.
26. Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004; 39: 1467-74.
27. Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49: 1688-93.
28. Maertens J, Deeren D, Dierickx D et al. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis 2006; 19: 551-6.
29. Lass-Flörl C, Resch G, Nachbaur D et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101-4.
30. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based pre-emptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-50.
31. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-74.
32. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-51.
33. White PL, Linton CJ, Perry MD et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 2006; 42: 479-86.
34. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
35. Herbrecht R, Fluckiger U, Gachot B et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. EJC Supplements 2007; 5: 49-59.
36. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
37. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 106: 2641-5.
38. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
39. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289-97.
40. Denning DW. Comparison of two studies of treatment of invasive aspergillosis. Clin Infect Dis 2007; 45: 1106-8.
41. Lass-Flörl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-7.
42. Viscoli C, Herbrecht R, Akan H et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64: 1274-81.
43. Herbrecht R, Maertens J, Baila L et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; 45: 1227-33.
44. Segal BH, Herbrecht R, Stevens DA et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47: 674-83.
45. Wingard JR. Learning from our failures: the antifungal treatment conundrum. Clin Infect Dis 2008; 46: 1434-5.
46. Miceli MH, Maertens J, Buvé K et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112-20.
47. Miceli MH, Grazziutti ML, Woods G et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46: 1412-22.
48. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
49. Troke P, Aguirrebengoa K, Arteaga C et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-50.
50. Spellberg B, Walsh TJ, Kontoyiannis DP et al. Clinical practice: recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 1743-51.